NICE | ESC | |
---|---|---|
Description | Two separate guidelines for diagnosis and management | Single guideline for diagnosis and management |
Publication date | March 2010 (diagnostic); July 2011 (management) | August 2013 |
Literature search date | To April 2009 (diagnostic); to 22 October 2010 (management) | Not stated |
Inclusions | Diagnostic guidelines:
| Stable angina Asymptomatic patients with known CAD Low-risk acute coronary syndrome patients (no ongoing chest pain, negative cardiac biomarkers, and a normal ECG) Asymptomatic patients with an abnormal test References made to microvascular dysfunction and coronary vasospasm |
Exclusions | Diagnostic guidelines:
| Not defined |
Cost effectiveness | An intervention was defined as cost effective if it was both less costly in resource use and more clinically effective compared with all relevant alternative strategies, or if it cost <£20 000 per quality-adjusted life year gained compared with the next best strategy | Not assessed |
Guidance | Simple statements | Statements usually associated with class of recommendation (I, IIa, IIb or III)* and level of evidence (A, B or C)† |
*I—is recommended; IIa—should be considered; IIb—may be considered; III—is not recommended.
†A—multiple randomised controlled trials or meta-analyses; B—single randomised controlled trial or large non-randomised studies; C—consensus of opinion and/or small studies/retrospective studies/registries.
CAD, coronary artery disease; ESC, European Society of Cardiology; NICE, National Institute for Health and Care Excellence.